BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1872 related articles for article (PubMed ID: 18316578)

  • 1. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
    Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
    Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of antiangiogenic therapies for the prevention of liver metastases.
    Mi J; Sarraf-Yazdi S; Zhang X; Cao Y; Dewhirst MW; Kontos CD; Li CY; Clary BM
    J Surg Res; 2006 Mar; 131(1):97-104. PubMed ID: 16242720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
    Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
    Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.
    Deryugina EI; Soroceanu L; Strongin AY
    Cancer Res; 2002 Jan; 62(2):580-8. PubMed ID: 11809713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
    Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the functions of endogenous angiogenesis inhibitors.
    Grant MA; Kalluri R
    Cold Spring Harb Symp Quant Biol; 2005; 70():399-410. PubMed ID: 16869777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
    Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
    Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.
    Etoh T; Inoue H; Tanaka S; Barnard GF; Kitano S; Mori M
    Cancer Res; 2001 Mar; 61(5):2145-53. PubMed ID: 11280779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.
    Kimura Y; Sumiyoshi M; Baba K
    Cancer Sci; 2008 Oct; 99(10):2083-96. PubMed ID: 19016770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of inhibition of tumor angiogenesis by beta-hydroxyisovalerylshikonin.
    Komi Y; Suzuki Y; Shimamura M; Kajimoto S; Nakajo S; Masuda M; Shibuya M; Itabe H; Shimokado K; Oettgen P; Nakaya K; Kojima S
    Cancer Sci; 2009 Feb; 100(2):269-77. PubMed ID: 19200258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H; Nagano H; Yamamoto H; Arai I; Ota H; Nakamura M; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Doki Y; Dono K; Nakamori S; Sakon M; Monden M
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas.
    Shikada Y; Yonemitsu Y; Koga T; Onimaru M; Nakano T; Okano S; Sata S; Nakagawa K; Yoshino I; Maehara Y; Sueishi K
    Cancer Res; 2005 Aug; 65(16):7241-8. PubMed ID: 16103075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
    Castle VP; Dixit VM; Polverini PJ
    Lab Invest; 1997 Jul; 77(1):51-61. PubMed ID: 9251678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
    Filleur S; Courtin A; Ait-Si-Ali S; Guglielmi J; Merle C; Harel-Bellan A; Clézardin P; Cabon F
    Cancer Res; 2003 Jul; 63(14):3919-22. PubMed ID: 12873985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.